MAGL Inhibitor Compound 23 |
| Katalog-Nr.GC41185 |
MAGL Inhibitor Compound 23 ist ein potenter, selektiver, reversibler und kompetitiver Inhibitor von MAGL mit einem IC50 von 80 nM. MAGL Inhibitor Compound 23 zeigt antiproliferative Wirkungen gegen menschliche Brust-, Darm- und Eierstockkrebszellen. MAGL Inhibitor Compound 23 blockiert MAGL sowohl in zellbasierten als auch in vivo-Assays.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2324160-91-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MAGL inhibitor compound 23 is an inhibitor of monoacylglycerol lipase (MAGL; IC50 = 80 nM). It is selective for MAGL over cannabinoid receptor 1 (CB1), CB2, fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing protein 6 (ABHD6), and ABHD12 (IC50s = >10 μM). MAGL inhibitor compound 23 inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM). It increases the levels of 2-arachidonoyl glycerol in mouse brain and plasma when administered at a dose of 50 mg/kg.
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *